Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6452W HIGH $18.33
Volume
15.04 K
Value Traded
10.58 M
Short % Float
16.42%
-0.73%Week
-27.84%1 Month
-22.43%3 Month
+29.13%6 Month
-32.31%5 Year
-32.31%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
629.73 M
EPS (TTM)
-1.00
P/E Ratio
-
Ent. Value
384.54 M
Total Shares
57.39 M
Float Shares
51.82 M
Insiders
9.78%
Institutions
95.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CLYM Catalyst Timeline
Dated clinical, regulatory and corporate events for Climb Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Climb Bio, Inc.
209Total events
12Upcoming
40Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutCLYM116Clinical Data
Initial Phase 1 data for CLYM116 announced
IgA nephropathysource ↗
▲First Patient DosedBudoprutugTrial
First patient dosed in China Phase 1b/2a trial of budoprutug in SLE
systemic lupus erythematosussource ↗
●Enrollment UpdateBudoprutugTrial
Enrollment ongoing in PrisMN Phase 2 trial
primary membranous nephropathysource ↗
◆Trial InitiationCLYM116Trial
CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing
IgA nephropathysource ↗
◆Trial InitiationBudoprutugTrial
Mabworks Phase 1/2 study: dosing of IgAN patients in Phase 2 portion expected to begin
IgA nephropathysource ↗
◆Poster PresentationBudoprutugPresentation
Poster presentation of initial Phase 1b study results for budoprutug in ITP at EHA 2026
primary immune thrombocytopeniasource ↗
▲Poster PresentationBudoprutugPresentation
Initial Phase 1b data presented at EHA Congress 2026
immune thrombocytopeniasource ↗
◆Enrollment UpdateBudoprutugTrial
Enrollment ongoing in 1000 mg cohort
immune thrombocytopeniasource ↗
◆Oral PresentationCLYM116Presentation
Focused oral presentation on CLYM116 PK/PD modeling and initial Phase 1 safety data at ERA 2026
IgA nephropathysource ↗
◆Poster PresentationBudoprutugPresentation
Trial-in-progress poster for PrisMN Phase 2 study of budoprutug in pMN at ERA 2026
primary membranous nephropathysource ↗
◆Topline ReadoutBudoprutugClinical Data
Initial data from ITP trial anticipated
immune thrombocytopenia (ITP)source ↗
◆Biomarker DataCLYM116Clinical Data
Initial biomarker and dosing interval data anticipated mid-year 2026
IgA nephropathysource ↗
▲Oral PresentationCLYM116Presentation
CLYM116 initial Phase 1 safety data presented at ERA Congress
IgA nephropathysource ↗
◆Topline ReadoutCLYM116Clinical Data
Initial healthy volunteer data for CLYM116 expected mid-2026
healthy volunteerssource ↗
▲Oral PresentationBudoprutugPresentation
Initial Phase 1b data in ITP presented at EHA Congress
immune thrombocytopeniasource ↗
▲Topline ReadoutBudoprutugClinical Data
Topline data from Phase 1 SC formulation trial in healthy volunteers
healthy volunteerssource ↗
▲Oral PresentationBudoprutugPresentation
Positive topline data for SC formulation of budoprutug presented at R&D Spotlight
autoimmune diseasessource ↗
▲Topline ReadoutBudoprutugClinical Data
Positive topline data for SC formulation of budoprutug presented at R&D Spotlight
autoimmune diseasessource ↗
▲Equity OfferingCorporate
Completed private placement financing generating approximately $110 million
▼Equity OfferingCorporate
Announced $110.0 million private placement of common stock and pre-funded warrants
▲Trial CompletionBudoprutugTrial
Subcutaneous formulation trial in healthy volunteers completed dosing
healthy volunteerssource ↗
◆Topline ReadoutBudoprutugClinical Data
Initial data from budoprutug Phase 2 PrisMN trial expected
primary membranous nephropathy (pMN)source ↗
▲First Patient DosedBudoprutugTrial
First patient dosed in China SLE study
systemic lupus erythematosussource ↗
▲Fast Track DesignationBudoprutugDesignation
Fast Track Designation granted by FDA for pMN
primary membranous nephropathysource ↗
▲Enrollment CompleteBudoprutugTrial
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation
healthy volunteerssource ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside Chat
▲First Patient DosedBudoprutugTrial
First patients dosed in budoprutug Phase 2 PrisMN trial in pMN
primary membranous nephropathy (pMN)source ↗
▲First Patient DosedCLYM116Trial
First patients dosed in CLYM116 Phase 1 healthy volunteer study
healthy volunteerssource ↗
▼Milestone PaymentBudoprutugCorporate
Alumis invoices $3 million milestone payment due January 1, 2026
◆IP Litigation RulingIP / Competition
Climb Bio files lawsuit against Alumis and Acelyrin over APA dispute
▲First Patient DosedCLYM116Trial
Anticipate dosing first subject in CLYM116 Phase 1 trial by year-end 2025
IgA Nephropathysource ↗
▲IND ClearanceBudoprutugIND
IND clearance in China for budoprutug SLE trial received in December 2025
systemic lupus erythematosussource ↗
●Oral PresentationBudoprutugPresentation
Phase 1b/2a ITP trial design detailed at 2025 ASH conference
immune thrombocytopeniasource ↗
▲First Patient DosedBudoprutugTrial
First patient dosed with budoprutug in Phase 2 clinical trial
immune-related diseasessource ↗
◆Poster PresentationCLYM116Presentation
Poster presentation of CLYM116 preclinical data at ASN Kidney Week 2025
IgA nephropathy (IgAN)source ↗
▲Trial InitiationBudoprutugTrial
Phase 1 trial of budoprutug subcutaneous formulation initiated
Immune-mediated diseasessource ↗
Past FDA Catalysts and PDUFA Decisions
How CLYM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-03 | CLYM116 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$226M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 22%
Micro Cap(rank 146 of 658)
Percentile Rank
Climb Bio, Inc. carries a moderate pipeline score (48/100), with $565M risk-adjusted pipeline value, led by ETX-018810 in Diabetic Peripheral Neuropathic Pain (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ETX-018810 Small moleculeCompletedNCT04778592 | Lumbosacral Radiculopathy | Phase 2 | COMPLETED | 149 | May 25, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every CLYM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CLYM116 | IgA nephropathy | Phase 1 | 2026-09-03 | ~29-day half-life; >90% free APRIL suppression following a single 320 mg dose; ~60-75% IgA, Gd-IgA1, and IgM suppression following a single 320 mg doseRead More | Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA NephropathyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.Director, 10% Owner | Option | 10,000 30,000 held | $7.89 | 09/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLYM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CLYM for Q2 2026. | ||||
CLYM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLYM ranks across every disease it competes in
Competitive Position is a premium feature
See how CLYM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLYM News
CLYMClimb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Climb Bio, Inc. will present new clinical data for its CLYM116 and budoprutug programs at the ASN Kidney Week 2026. The presentations include preliminary Phase 2 data from the PrisMN study of budoprutug for primary membranous nephropathy and updates on CLYM116 for IgA nephropathy. The event will take place in Denver, Colorado from October 21-25, 2026.
Read more →CLYMClimb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
Climb Bio announced positive Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody, demonstrating a ~29-day half-life and significant APRIL suppression. The drug showed a favorable safety profile with no serious adverse events. The company is advancing to Phase 2 trials and plans to initiate a Phase 3 study in 2027.
Read more →CLYMClimb Bio to Present at Upcoming Investor Conferences
Climb Bio, Inc. will present at two upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The company's executive team will participate in fireside chats, providing insights into their clinical-stage biotechnology developments. Climb Bio focuses on therapeutics for immune-mediated diseases, with a pipeline that includes innovative monoclonal antibodies.
Read more →CLYM▲ +12.3%on this news
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Climb Bio reported its second quarter 2026 financial results, highlighting significant progress in its clinical programs, particularly CLYM116 for IgA nephropathy. The company anticipates initiating a Phase 2 trial for CLYM116 in Q3 2026 and expects data from multiple ongoing studies in Q4 2026. Climb Bio's financial position remains strong, with a cash runway extended into the second half of 2028.
Read more →CLYMClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Climb Bio announced initial Phase 1b data for budoprutug, showing a favorable safety profile and significant B-cell depletion in patients with primary immune thrombocytopenia (ITP). The data, presented at the EHA Congress 2026, indicate promising platelet responses, especially in patients previously treated with rituximab. Enrollment in the study's high-dose cohort is ongoing, with further data expected by the end of 2026.
Read more →CLYMCLIMB BIO, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
Climb Bio, Inc. has adopted a new Equity Incentive Plan as approved by the Compensation Committee of the Board of Directors. This plan is a continuation of the previous plan and is designed to secure and retain talent, including employees, directors, and consultants. It allows for various award types such as Incentive Stock Options and Restricted Stock Awards, with a total of approximately 5.2 million shares available. The plan is structured to provide annual increases in shares awarded over the next decade to continually engage and incentivize eligible participants.
Read more →CLYMClimb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Read more →CLYMClimb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
Climb Bio, Inc. will present its CLYM116 and budoprutug programs at the European Renal Association Congress 2026 in Glasgow. The presentations will include pharmacokinetic modeling and initial safety data from the CLYM116 Phase 1 study, as well as a trial-in-progress poster for the Phase 2 study of budoprutug in primary membranous nephropathy. These developments reflect Climb Bio's commitment to addressing immune-mediated diseases.
Read more →CLYMClimb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
Climb Bio, Inc. will present new clinical data on its budoprutug program at the EHA 2026 Congress in Stockholm. The data will include safety and efficacy results from a Phase 1b/2a trial focusing on patients with immune thrombocytopenia. Budoprutug, an anti-CD19 monoclonal antibody, has shown promise in treating various B-cell mediated diseases.
Read more →CLYMClimb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Climb Bio, Inc. has reported its financial results for the first quarter of 2026, highlighting significant advancements in its clinical programs. The company observed robust B-cell depletion in trials for budoprutug, an anti-CD19 monoclonal antibody, and secured $110 million in new financing. Ongoing trials for budoprutug in primary membranous nephropathy and immune thrombocytopenia are on track, with key data expected throughout 2026. Additionally, progress in the CLYM116 program is set to be presented at the European Renal Association Congress in June 2026.
Read more →CLYM▲ +18.2%on this newsshared move
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
Climb Bio, Inc. has announced promising updates on budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated diseases. At a recent R&D Spotlight event, the company showcased positive topline data from a subcutaneous formulation trial, indicating robust B-cell depletion in healthy volunteers. Budoprutug is currently undergoing clinical trials for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, with Fast Track Designation granted for pMN. The company anticipates initial data releases from trials in the near future, highlighting a significant opportunity within the immune-mediated disease landscape.
Read more →CLYM▲ +18.2%on this newsshared move
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-cell Mediated Disease Opportunity, and Upcoming Data Readouts
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-cell Mediated Disease Opportunity, and Upcoming Data Readouts
Read more →CLYMClimb Bio, Inc. Announces $110.0 Million Private Placement
Climb Bio, Inc. has announced a private placement of approximately $110 million with institutional investors. The placement involves selling 9,481,000 shares of common stock at $9.50 each, along with pre-funded warrants. The proceeds will support the company's development of therapeutics for immune-mediated diseases. The closing is expected on April 29, 2026, pending customary conditions.
Read more →CLYMClimb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Climb Bio, Inc. will host a webcast on May 5, 2026, focusing on its budoprutug program, which targets B-cell mediated diseases. The event will feature insights on the clinical potential of budoprutug in treating conditions like primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. The webcast will also discuss ongoing studies and the company's development strategy.
Read more →CLYMClimb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Read more →CLYMClimb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Climb Bio reported its fourth quarter and full year 2025 financial results, highlighting a strong cash position expected to fund operations into 2028. The company has completed dosing in a Phase 1 study of budoprutug's subcutaneous formulation and is conducting multiple trials for this and CLYM116. Initial data from these trials is anticipated in 2026.
Read more →CLYM▲ +9%on this news· ran to +20% by day 1
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
Climb Bio has announced significant progress in its pipeline and strategic plans for 2026, including the dosing of first patients in the budoprutug Phase 2 trial for primary membranous nephropathy. The company highlighted its strong financial position, expecting cash resources to last until 2028, and indicated a data-rich year ahead with several trial readouts anticipated. Climb Bio's achievements include obtaining 20 regulatory approvals for clinical trials and advancing its other candidate, CLYM116, into the clinic. Ongoing trials are aimed at addressing unmet needs in immune-mediated diseases.
Read more →About Climb Bio, Inc.
Headquarters20 WILLIAM STREET, WELLESLEY HILLS, MA, 02481
BIOPHARMAWATCH ELITE PLUS
Trade the next CLYM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime